Palmitoyl Tetrapeptide-7
What the Research Actually Shows
Human: 1 studies, 2 groups · Animal: 1 · In Vitro: 5
The anti-inflammatory immunoglobulin fragment that anchors the other half of Matrixyl 3000 — with a compelling theoretical rationale, zero independent human evidence, and the same attribution problem from the other side of the equation
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Palmitoyl Tetrapeptide-7 is a small peptide designed to calm inflammation in aging skin. Its sequence — GQPR — is borrowed from immunoglobulin proteins that help regulate your immune system. In lab dishes, it reduces the inflammatory signals (especially IL-6) that UV exposure and aging trigger in skin cells. The catch: this ingredient has never been tested alone in a human clinical trial. Every positive result comes from Matrixyl 3000 — a two-peptide blend that also contains Pal-GHK, a collagen-stimulating peptide with stronger independent biology. Whether Pal-GQPR contributes meaningfully to that combination, or whether it is a supporting actor overshadowed by a better-studied partner, remains entirely unknown.
If Palmitoyl Tripeptide-1 is the collagen-builder in the Matrixyl 3000 formula, Palmitoyl Tetrapeptide-7 is the peacekeeper — designed to suppress the chronic low-grade inflammation that degrades collagen faster than new collagen can replace it. The division of labor is elegant: one peptide stimulates repair, the other quiets the damage signals. Both peptides are palmitoylated — conjugated to a fatty acid tail — for improved penetration through the skin's oily barrier.
The theoretical rationale is sound. IL-6 suppression and MMP-1 inhibition are validated targets in skin aging research. UV radiation activates inflammatory pathways that upregulate collagen-degrading enzymes; an ingredient that dampens those pathways should, in principle, protect the dermal scaffold. The GQPR sequence draws from immunoglobulin-like domains known to modulate immune responses.
The problem is evidentiary, not conceptual. Pal-GQPR has never been tested alone in a human trial. The in vitro mechanism work is almost entirely proprietary (Sederma, the manufacturer). Independent peer-reviewed validation of GQPR's specific targets and binding behavior is minimal. And in the Matrixyl 3000 combination, Pal-GHK — whose underlying biology (GHK matrikine signaling) is well-characterized across multiple labs — may be doing most of the work.
For a deeper understanding of how topical peptides navigate the skin barrier — and how microneedling can dramatically improve delivery — see our [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/) guide.
In This Article
Quick Facts: Palmitoyl Tetrapeptide-7 at a Glance
Type
Lipopeptide (palmitoylated tetrapeptide); proposed immunoglobulin-derived anti-inflammatory
Also Known As
Pal-GQPR, Palmitoyl Tetrapeptide-3 (outdated nomenclature), Rigin component, Matrixyl 3000 component (peptide 2 of 2)
Generic Name
Palmitoyl tetrapeptide-7
Brand Name
Marketed as a component of Matrixyl 3000 (Sederma/Ashland Inc.); formerly part of Haloxyl in some blends
Molecular Weight
~687 Da (GQPR core: ~399 Da + palmitoyl chain: ~273 Da)
Peptide Sequence
Palm-Gly-Gln-Pro-Arg (palmitoyl-glycine-glutamine-proline-arginine)
Endogenous Origin
GQPR is not a known endogenous peptide; the sequence is designed to mimic immunoglobulin-derived anti-inflammatory domains
Primary Molecular Function
Proposed: IL-6 suppression in UV-exposed keratinocytes; MMP-1 inhibition; anti-inflammatory immune modulation via Ig-like activity
Active Fragment
GQPR tetrapeptide is the proposed active core; palmitoyl chain enhances lipophilicity for skin penetration
Delivery Methods
Topical (primary) · Microneedling-enhanced topical (theoretical benefit) · Not used as injectable
Clinical Programs
No independent clinical trials for Pal-GQPR alone; all human data from Matrixyl 3000 (Pal-GHK + Pal-GQPR combination), manufacturer-funded panels
Route
Topical application in cream, serum, or mask formulations; typically at 0.01–0.1% active peptide
FDA Status
Cosmetic ingredient under INCI/CIR; not a drug; not FDA-approved for any therapeutic indication
WADA Status
Not prohibited (cosmetic, topical, no systemic absorption, no ergogenic effect)
Community Interest
Anti-inflammatory skincare — marketed as an ingredient that calms UV-damaged and aging skin by suppressing inflammatory cytokines
Penetration Challenge
Palmitoylation improves lipophilicity but in vivo dermal penetration of Pal-GQPR has never been measured in humans; whether sufficient peptide reaches target keratinocytes is unvalidated
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Palmitoyl Tetrapeptide-7? — Origins and Discovery
Pronunciation: PAL-mih-toyl TET-ruh-pep-tide seven
Your skin is in a constant state of low-grade war. Ultraviolet light hits the surface and triggers an inflammatory cascade — keratinocytes release IL-6 and TNF-α, fibroblasts respond by upregulating matrix metalloproteinases (MMPs) that chew through collagen, and the dermal scaffold weakens a little bit more with each exposure. Over years and decades, this process — photoaging — accounts for more visible skin aging than chronological aging itself.
Palmitoyl Tetrapeptide-7 was designed to interrupt that cascade. The peptide's core sequence — glycine-glutamine-proline-arginine, or GQPR — is drawn from immunoglobulin domains, the structural units that antibodies and immune-regulatory proteins are built from. Immunoglobulin fragments have long been known to modulate inflammatory responses, and the idea behind GQPR was to capture that anti-inflammatory activity in a four-amino-acid package small enough to deliver through the skin.
The name has changed over the years. Originally classified as Palmitoyl Tetrapeptide-3, it was renamed Palmitoyl Tetrapeptide-7 under updated INCI nomenclature. Most consumers encounter it not by name but as the second peptide in Matrixyl 3000 — paired with Palmitoyl Tripeptide-1 (Pal-GHK), a collagen-stimulating matrikine. The combination was developed by Sederma, a French cosmeceutical company now part of Ashland Inc., and has been a mainstay of premium anti-aging formulations for over a decade.
What Sederma does not advertise is how little independent evidence exists for GQPR specifically. The immunoglobulin-mimicry rationale is theoretical — no peer-reviewed study has identified GQPR's precise molecular target, binding affinity, or mechanism of action with the rigor that, say, GHK's matrikine biology has received.
PLAIN ENGLISH
UV light triggers inflammation in your skin, and that inflammation breaks down collagen over time. Palmitoyl Tetrapeptide-7 is designed to calm that inflammation. The idea is sound — borrowed from the way immune proteins naturally regulate inflammation. But the ingredient itself has never been proven to work in human skin on its own.
Mechanism of Action
IL-6 Suppression: The Central Claim
The primary mechanism attributed to Pal-GQPR is suppression of interleukin-6 (IL-6) in epidermal keratinocytes. IL-6 is a pleiotropic cytokine — it signals inflammation, stimulates immune cell recruitment, and activates downstream pathways including NF-κB, STAT3, and MAPK signaling. In the skin aging context:
1. UV exposure rapidly induces IL-6 secretion from keratinocytes (PMID 18571053). This is a well-characterized response — UVB penetrates the epidermis, damages DNA, and triggers an inflammatory alarm system.
2. IL-6 upregulates MMP expression in dermal fibroblasts. Specifically, IL-6 drives MMP-1 (interstitial collagenase) production, which degrades type I and type III collagen — the structural proteins that give skin its firmness. Over repeated UV exposures, cumulative MMP activity thins the dermal collagen layer.
3. Pal-GQPR is claimed to interrupt this cascade by suppressing IL-6 release from keratinocytes before it reaches fibroblasts and activates MMP production. If effective, this would preserve collagen architecture by preventing the upstream inflammatory signal.
MMP-1 Inhibition
Secondary to IL-6 suppression, Pal-GQPR is proposed to directly or indirectly reduce MMP-1 expression. Whether this is a direct effect of GQPR on fibroblast MMP regulation or an indirect consequence of reduced IL-6 signaling is not distinguished in available data.
Immunoglobulin-Derived Peptide Activity
The GQPR sequence was selected for its structural similarity to immunoglobulin constant region fragments. Immunoglobulin-derived peptides have demonstrated anti-inflammatory and immune-modulating activity in general peptide immunology research (PMID 20414882). The specific hypothesis is that GQPR mimics an Ig-like domain that can bind pattern recognition receptors or soluble inflammatory mediators, dampening the inflammatory response.
Critical assessment: The Ig-mimicry mechanism is a theoretical rationale. No published study identifies GQPR's binding target, demonstrates receptor interaction kinetics, or characterizes the molecular basis of its claimed anti-inflammatory activity. The mechanism is borrowed by analogy from immunoglobulin biology — not proven for this specific sequence.
The Palmitoylation Question
As with all Cluster G palmitoylated peptides, the fatty acid tail is a delivery modification. Palmitoylation enhances cellular uptake in fibroblast and keratinocyte cultures (PMID 25677065). Whether the enhanced uptake translates to meaningful dermal delivery through intact human skin is unmeasured.
PLAIN ENGLISH
The idea: UV light triggers inflammation in skin cells, that inflammation tells other cells to break down collagen, and Pal-GQPR is supposed to intercept the inflammation before the collagen damage happens. The theory makes biological sense. The problem is that nobody has specifically proven that this four-amino-acid peptide actually does what the theory predicts when applied to human skin.
Key Research Areas and Studies
In Vitro Evidence: Proprietary and Unvalidated
The evidence base for Pal-GQPR is thin compared to its partner Pal-GHK. Most mechanism data are proprietary (Sederma) and have not been independently replicated.
IL-6 suppression (Sederma proprietary data): GQPR reportedly suppresses IL-6 secretion in UVB-exposed normal human keratinocyte cultures. Dose and magnitude data are not publicly available. This is the core claim supporting the ingredient, and it rests on non-peer-reviewed manufacturer studies.
MMP-1 inhibition (Matrixyl 3000 combination): In vitro data on the Pal-GHK + Pal-GQPR combination show reduced MMP-1 expression in fibroblast cultures. Because both peptides are present, Pal-GQPR's independent contribution cannot be isolated. Pal-GHK (via GHK matrikine biology) has established MMP-suppressing activity on its own (PMID 22585060).
Supporting Literature: General, Not Specific
UV-induced IL-6 in keratinocytes (PMID 18571053): UVB rapidly induces IL-6 and TNF-α in cultured human keratinocytes. This validates the target — IL-6 suppression is biologically relevant to photoaging. But this study tested UV effects, not GQPR.
MMP-1 and photoaging (PMID 16005892): Chronic UV exposure upregulates MMP-1 and degrades dermal collagen. MMP inhibition preserves collagen architecture. Again, target validation — not Pal-GQPR-specific evidence.
Tetrapeptide anti-inflammatory activity (PMID 22301543): Modified tetrapeptides show dose-dependent IL-6 suppression in cell culture. This supports the general principle that short peptides can suppress inflammatory cytokines. The specific GQPR sequence is not the subject of this study.
Immunoglobulin-derived peptides (PMID 20414882): Review of Ig-like peptide anti-inflammatory properties. Supports the theoretical framework for Pal-GQPR's design but does not validate GQPR itself.
Matrixyl 3000 Clinical Data
Sederma panel (~2010): 45 subjects, randomized, placebo-controlled, 12 weeks. Matrixyl 3000 (Pal-GHK + Pal-GQPR) showed approximately 52% wrinkle reduction and improved skin firmness. This is the only human data remotely connected to Pal-GQPR.
The attribution problem — viewed from Pal-GQPR's side: Pal-GHK has independent in vitro evidence for collagen stimulation across multiple labs. Pal-GQPR does not have independent in vitro evidence beyond manufacturer claims. If one had to guess which peptide contributes more to Matrixyl 3000's clinical results, the evidence favors Pal-GHK. But this is inference, not proof.
PLAIN ENGLISH
The in vitro evidence supporting this ingredient is mostly proprietary — produced by the company that sells it — and has not been checked by independent researchers. The human evidence comes from a combination product where the other ingredient (Pal-GHK) has stronger independent science. That does not mean Pal-GQPR does nothing. It means nobody has done the work to prove it does something.
The Partnership Problem — Palmitoyl Tetrapeptide-7 in Matrixyl 3000
Always the Second Name
Palmitoyl Tetrapeptide-7 exists commercially almost exclusively as the second component of Matrixyl 3000. It is rarely formulated alone. This creates a fundamental evidence problem: every clinical result is shared credit, and the ingredient with weaker independent biology cannot claim its share.
The Complement Hypothesis
Sederma's rationale for combining Pal-GHK (collagen stimulation) with Pal-GQPR (anti-inflammation) is logical:
1. Pal-GHK stimulates fibroblasts to produce new collagen 2. Pal-GQPR suppresses the inflammatory signals that would otherwise degrade that collagen 3. Together, they create a build-and-protect strategy
This is biologically elegant. But "biologically elegant" and "proven in humans" are different categories. The complement hypothesis has never been tested with a factorial study design (Pal-GHK alone vs. Pal-GQPR alone vs. combination vs. placebo).
Compared to Its Partner
| Feature | Pal-GHK (Palmitoyl Tripeptide-1) | Pal-GQPR (Palmitoyl Tetrapeptide-7) |
|---|---|---|
| Core peptide | GHK — natural matrikine | GQPR — synthetic Ig-mimic |
| Endogenous role | Yes (collagen fragment) | No known endogenous source |
| Multi-lab in vitro | Yes (extensive) | No (proprietary only) |
| Mechanism specificity | High (integrin binding, collagen stimulation) | Low (general anti-inflammatory claim) |
| Independent human data | None (combination only) | None (combination only) |
| Overall evidence weight | Stronger | Weaker |
PLAIN ENGLISH
Think of Matrixyl 3000 as a band with two members. One (Pal-GHK) has a strong solo career — well-known, well-reviewed, solid body of work. The other (Pal-GQPR) has only ever performed as part of the duo. The band's albums sell well. But if you had to bet on which member is carrying the act, the evidence points toward the one with the solo career.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Reduces skin inflammation"” | In vitro: proprietary data claim IL-6 suppression in keratinocytes. Not independently replicated. General tetrapeptide anti-inflammatory literature supports the concept, not the specific ingredient. | Mixed Evidence |
| “"Protects collagen from UV damage"” | IL-6 and MMP-1 are validated photoaging targets. Whether Pal-GQPR suppresses them in human skin: not tested. | Theoretical |
| “"Reduces wrinkles and improves skin texture"” | Matrixyl 3000 (Pal-GHK + Pal-GQPR) shows wrinkle reduction in manufacturer panels. Pal-GQPR alone: no data. | Mixed Evidence |
| “"Anti-aging peptide based on immune proteins"” | GQPR is designed to mimic Ig domains. Whether it actually functions as an Ig-mimic in skin: unproven. The design rationale is theoretical. | Theoretical |
| “"Calms UV-damaged skin"” | UV triggers IL-6 in keratinocytes — well-established. Whether topical Pal-GQPR suppresses this in vivo: not tested. | Preclinical Only |
| “"Complements Pal-GHK for comprehensive anti-aging"” | The build-and-protect rationale is biologically logical. But no factorial study tests whether the combination outperforms either peptide alone. | Theoretical |
| “"Clinically proven in Matrixyl 3000"” | Matrixyl 3000 has clinical panel data. Attributing that proof to Pal-GQPR specifically is incorrect — attribution is unresolved. | Mixed Evidence |
| “"Reduces MMP-1 (collagenase)"” | MMP-1 inhibition is demonstrated for Matrixyl 3000 in vitro. Independent Pal-GQPR MMP-1 data: not available. Pal-GHK (via GHK) has independent MMP-1 evidence. | Preclinical Only |
| “"Safe and well-tolerated"” | Excellent safety profile over two decades of commercial use. No irritation, no sensitization, no adverse effects reported. | Supported |
| “"Better than hyaluronic acid for anti-aging"” | Different mechanisms entirely. HA hydrates; Pal-GQPR (if effective) suppresses inflammation. No comparison study exists. False dichotomy. | Unsupported |
| “"Works at the molecular level"” | All compounds work at the molecular level. This is a marketing tautology. The question is whether topical Pal-GQPR reaches its molecular targets in human skin. | Mixed Evidence |
| “"Backed by immunology research"” | General immunoglobulin peptide research exists. Specific GQPR immunology: minimal. The ingredient borrows credibility from a broader field without contributing to it. | Mixed Evidence |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
No Independent Human Evidence
Palmitoyl Tetrapeptide-7 has no clinical trial testing it as a standalone ingredient. Zero. Every human data point is confounded by the presence of Palmitoyl Tripeptide-1 (Pal-GHK) in the same formulation.
Matrixyl 3000: The Shared Evidence
The best human evidence comes from the Sederma clinical panel (~2010): 45 subjects, randomized against placebo, 12 weeks. Wrinkle depth decreased approximately 52%. Skin firmness and elasticity improved. Additional manufacturer panels (20–60 subjects, 2008–2015) show consistent improvements.
These results are real and reproducible within the manufacturer's study system. But they answer the question "Does Matrixyl 3000 work?" — not "Does Pal-GQPR work?"
The Attribution Gap Is Wider from This Side
Pal-GHK (the collagen-stimulating partner) has: - Multi-lab in vitro evidence for collagen stimulation, MMP suppression, and anti-inflammatory activity - A well-characterized endogenous biological role (matrikine signaling) - A known receptor (integrin α2β1)
Pal-GQPR has: - Proprietary in vitro data (not independently replicated) - A theoretical mechanism (Ig-mimicry, not validated) - No identified receptor target
If the Matrixyl 3000 clinical benefit were attributed entirely to Pal-GHK, the biological evidence would support that conclusion. If attributed entirely to Pal-GQPR, no independent evidence would support it. This asymmetry explains why Pal-GHK earns "Reasonable Bet" and Pal-GQPR earns "Eyes Open."
What Would Advance the Evidence
A standalone clinical trial for Pal-GQPR would be the single most impactful study. A factorial Matrixyl 3000 design (Pal-GHK vs. Pal-GQPR vs. combination vs. placebo) would resolve attribution for both ingredients simultaneously.
PLAIN ENGLISH
This ingredient has never been tested alone in humans. The positive results people cite come from a two-ingredient product. The other ingredient has much stronger independent science. That does not prove Pal-GQPR is useless — but it means the evidence for it specifically is weaker than its marketing suggests.
Safety, Risks, and Limitations
Excellent Safety Profile
Pal-GQPR has two decades of commercial use in cosmetic formulations with no reported safety concerns.
Dermal safety: Non-irritating at cosmetic concentrations (0.01–0.1% w/v active peptide). Compatible with sensitive skin. Allergic potential: No reported contact sensitization in published safety reviews or post-market surveillance. Systemic exposure: Negligible. Topical peptide absorption through intact skin is minimal at MW ~687 Da. Photosensitivity: None. Pal-GQPR is not a photosensitizing agent. Pregnancy and lactation: No specific data. Theoretical risk is negligible given minimal systemic absorption from topical cosmetic use. Drug interactions: None documented. Topical cosmetic peptides do not interact with systemic medications.
Limitations
The limitations of Pal-GQPR are evidentiary, not safety-related: - No independent clinical evidence - Proprietary mechanism data not replicated by academic labs - Attribution problem in all combination-product results - Unknown whether cosmetic concentrations deliver biologically meaningful amounts to target cells
PLAIN ENGLISH
This ingredient is safe — no rashes, no allergies, no problems reported over twenty years of use in skincare products. The honest limitation is not safety but uncertainty about whether it does what the marketing claims.
Legal and Regulatory Status
FDA Classification
Palmitoyl Tetrapeptide-7 is a cosmetic ingredient regulated under the INCI/CIR system. It is not a drug. Products containing Pal-GQPR may claim to "reduce the appearance of" wrinkles, "soothe" skin, and "support skin resilience" but may not claim to "reduce inflammation," "treat" aging, or "heal" skin.
International Status
Accepted for cosmetic use in the European Union (EC 1223/2009), China, Canada, Japan, and Australia. No restrictions. Widely available in global skincare formulations as a component of Matrixyl 3000.
WADA Status
Not prohibited. Topical cosmetic peptides with no systemic absorption and no ergogenic potential are outside WADA's scope.
Research Protocols and Formulation Considerations
Typical Formulation
Pal-GQPR is almost always supplied as part of the Matrixyl 3000 blend (1:1 molar ratio with Pal-GHK). Standalone Pal-GQPR raw material is available from peptide synthesis suppliers but is rarely formulated independently in consumer products. Typical inclusion rate: 0.01–0.1% active peptide in finished cosmetic formulations.
Stability
Peptide stability is maintained at pH 4.5–6.5, compatible with the skin's natural acid mantle. GQPR is susceptible to proteolytic degradation by skin proteases. Formulations should include antioxidants (vitamin E, ferulic acid) and chelating agents to preserve peptide integrity. Sealed packaging with UV protection extends shelf life.
Delivery Enhancement
As with all Cluster G topical peptides, the stratum corneum barrier limits delivery. Enhanced methods: - Microneedling: Creates transient channels bypassing the stratum corneum; theoretical benefit for all topical peptides - Liposomal encapsulation: Some premium formulations use lipid carriers - Penetration enhancers: Niacinamide, glycolic acid, or other formulation-level enhancers
For comprehensive guidance on microneedling and topical peptide delivery, see [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/).
Dosing in Published Research
In Vitro Concentrations
| Context | Concentration | Notes |
|---|---|---|
| IL-6 suppression (keratinocytes) | Not publicly disclosed | Sederma proprietary data |
| MMP-1 inhibition (Matrixyl 3000) | 1–10 µM (combination) | Both peptides present |
| Commercial formulation | 0.01–0.1% w/v | Active peptide in finished product |
No Human Dose-Response Data
No clinical study has evaluated different concentrations of Pal-GQPR to determine optimal dosing. Product concentrations are based on manufacturer recommendations extrapolated from in vitro work.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Palmitoyl Tetrapeptide-7 has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Community Usage Patterns
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Topical (Matrixyl 3000 serum) | Twice daily to face, neck, décolleté | Combination clinical data | 0.01–0.1% active in product | None documented |
| Topical + microneedling | After derma-roller/pen session | Theoretical benefit | Same concentration | Microneedling risks; peptide delivery uncharacterized |
| Standalone Pal-GQPR serum | Rare; some DIY formulators | No independent data | Variable | No quality control; unproven efficacy |
| Combined with retinol | Sequential use (peptide AM, retinol PM) | No interaction data; common protocol | Standard concentrations | No known interaction concerns |
Community Perception
Pal-GQPR is far less well-known than its partner Pal-GHK. Most consumers recognize Matrixyl 3000 but do not distinguish between its two components. In skincare communities, Pal-GQPR is occasionally discussed as the "anti-inflammatory half" of the formula, but standalone products are uncommon.
PLAIN ENGLISH
Most people use this ingredient without knowing it — as part of Matrixyl 3000 in anti-aging serums. The typical use is twice daily on the face, mirroring how the combination was tested.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Palmitoyl Tetrapeptide-7 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Palmitoyl Tetrapeptide-7 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Palmitoyl Tetrapeptide-7 Compares
Palmitoyl Tetrapeptide-7 belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Skin & Cosmetic cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Argireline | Acetyl Hexapeptide-3 (Ac-EEMQRR-NH2); 889 Da | Tier 3 — Limited Human Data | Reasonable Bet | SNAP-25 mimetic → inhibits SNARE complex assembly → reduces ACh release at NMJ; topical 'botox-like' effect without cleaving SNARE | Expression wrinkle reduction; forehead and crow's feet | ~200 in clinical studies; 10–30% wrinkle reduction in 4 weeks | Not approved as drug (cosmetic ingredient; INCI listed) | Not prohibited | Penetration to dermal-epidermal junction unproven; effect magnitude far less than injectable botulinum toxin; manufacturer-sponsored studies |
| Matrixyl | Palmitoyl Pentapeptide-4 (Pal-KTTKS); 802 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — KTTKS collagen fragment stimulates fibroblast collagen I/III/IV synthesis + fibronectin + glycosaminoglycans; palmitoyl enhances penetration | Wrinkle reduction; collagen stimulation; skin texture improvement | ~150 in clinical studies; comparable to retinol in head-to-head | Not approved as drug (cosmetic ingredient) | Not prohibited | Primarily manufacturer-sponsored studies; independent validation limited; comparisons to retinol, not vehicle alone |
| Matrixyl 3000 | Palmitoyl Tetrapeptide-7 + Palmitoyl Tripeptide-1 (Pal-GQPR + Pal-GHK); blend | Tier 3 — Limited Human Data | Reasonable Bet | Dual action: Pal-GHK (matrikine collagen stimulation) + Pal-GQPR (IL-6 suppression + MMP-1 inhibition); build collagen while preventing degradation | Wrinkle reduction; anti-aging; skin firmness | ~120 in clinical studies; 22–28% wrinkle reduction | Not approved as drug (cosmetic ingredient) | Not prohibited | Proprietary blend (exact ratios undisclosed); primarily manufacturer data; less independent validation than Matrixyl |
| SNAP-8 | Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH2); 1,075 Da | Tier 4 — Preclinical Only | Eyes Open | Extended SNAP-25 mimetic (8 vs 6 AA); claimed greater SNARE inhibition than Argireline; same mechanism, additional binding contacts | Expression wrinkle reduction (claimed superior to Argireline) | None — zero peer-reviewed human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero published human efficacy data; larger MW may worsen skin penetration; marketed as 'superior' without human validation |
| Leuphasyl | Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu); 569 Da; enkephalin analog | Tier 4 — Preclinical Only | Thin Ice | Mu-opioid receptor agonist on sensory nerve terminals → reduces ACh release via presynaptic inhibition; different upstream mechanism than Argireline | Expression wrinkle reduction (Argireline synergist) | None — zero published human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Opioid receptor agonist topically — penetration to dermal nerve terminals undemonstrated; no independent data; marketed only as Argireline booster |
| Palmitoyl Tripeptide-1 | Pal-GHK (Biopeptide-CL); 578 Da | Tier 3 — Limited Human Data | Reasonable Bet | GHK matrikine signaling → fibroblast collagen synthesis + ECM remodeling; palmitoyl enhances skin penetration; GHK-Cu without the copper | Collagen stimulation; anti-aging; wound healing signal | ~80 in clinical studies (mostly in Matrixyl 3000 combo) | Not approved as drug (cosmetic ingredient) | Not prohibited | Usually studied in combination (Matrixyl 3000); hard to isolate individual contribution; GHK-Cu has more independent research |
| Palmitoyl Tetrapeptide-7 | Pal-GQPR; 687 Da; IgG fragment mimic | Tier 3 — Limited Human Data | Eyes Open | Anti-inflammatory: reduces IL-6 keratinocyte secretion + suppresses UVB inflammation + inhibits MMP-1 collagenase expression | Anti-inflammatory; collagen preservation; UVB damage reduction | ~60 (only as part of Matrixyl 3000 combination) | Not approved as drug (cosmetic ingredient) | Not prohibited | Never studied independently of Pal-GHK partner; clinical contribution unknown; anti-inflammatory mechanism plausible but unvalidated alone |
| Syn-Ake | Dipeptide Diaminobutyroyl Benzylamide Diacetate; ~390 Da | Tier 4 — Preclinical Only | Eyes Open | Claimed nAChR antagonism mimicking waglerin-1 (temple viper venom) → muscle relaxation → reduced expression lines | Expression wrinkle reduction ('snake venom–inspired') | 1 unpublished manufacturer panel study (~45 subjects) | Not approved as drug (cosmetic ingredient) | Not prohibited | Marketing narrative ('snake venom') far exceeds evidence; structural resemblance to waglerin-1 is minimal; zero peer-reviewed data; nAChR blockade unverified |
| Acetyl Tetrapeptide-5 | Ac-β-Ala-His-Ser-His (Eyeseryl); ~493 Da | Tier 4 — Preclinical Only | Eyes Open | Anti-edema: reduces vascular permeability + fluid accumulation; anti-glycation of capillary walls; targets periorbital puffiness | Under-eye puffiness (de-puffing); periorbital application | None — manufacturer panel data only (unpublished) | Not approved as drug (cosmetic ingredient) | Not prohibited | No peer-reviewed evidence; mechanism (anti-edema via glycation inhibition) is speculative; marketed for very specific niche (eye bags) |
| Palmitoyl Hexapeptide-12 | Palmitoyl Hexapeptide-12; ~921 Da | Tier 4 — Preclinical Only | Thin Ice | Proposed collagen + hyaluronic acid synthesis stimulation; adhesion molecule expression for dermal-epidermal junction integrity | Anti-aging; collagen stimulation (unvalidated) | None — zero evidence of any kind | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero peer-reviewed data; no mechanism validation; no manufacturer claims with detail; exists on ingredient lists by category association only |
| AHK-Cu | Ala-His-Lys-Cu²⁺; ~428 Da; copper tripeptide | Tier 4 — Preclinical Only | Thin Ice | Copper tripeptide signaling → proposed collagen/elastin synthesis via LOX activation; GHK-Cu analog with different N-terminal residue | Hair growth; wound healing; collagen stimulation | None — zero published human studies for AHK-Cu specifically | Not approved as drug (cosmetic ingredient) | Not prohibited | Evidence borrowed from GHK-Cu; no independent validation for AHK specifically; alanine substitution impact unknown; most marketing cites GHK-Cu data |
| Tripeptide-29 | Gly-Pro-Hyp (collagen tripeptide); ~285 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — most abundant collagen repeat; stimulates fibroblast collagen I synthesis + anti-glycation (AGE reduction) + MMP inhibition | Collagen stimulation; anti-aging; anti-glycation; skin hydration | ~202 across 4 studies (1 topical pilot N=22; 3 oral RCTs N=32–84) | Not approved as drug (cosmetic/GRAS ingredient) | Not prohibited | Topical study uncontrolled; oral RCTs test multi-component hydrolysates (3–15% Gly-Pro-Hyp), not isolated tripeptide; low oral bioavailability (4.4%) |
Frequently Asked Questions
Summary of Key Findings
Palmitoyl Tetrapeptide-7 is a palmitoylated tetrapeptide designed to suppress inflammation in aging and UV-damaged skin. Its proposed mechanism — IL-6 suppression in keratinocytes, leading to reduced MMP-1 activity and collagen preservation — targets validated pathways in skin aging research. The theoretical rationale is sound.
The evidence base, however, is thinner than marketing suggests. The in vitro mechanism work is almost entirely proprietary (Sederma) and has not been independently replicated by academic researchers. The ingredient's binding target, receptor interaction, and specific molecular mechanism remain uncharacterized in peer-reviewed literature. GQPR's design is inspired by immunoglobulin biology — a "borrowed credibility" strategy that sounds scientific but has not been validated for this specific sequence.
Human clinical data exists only for Matrixyl 3000 — a combination of Pal-GQPR and Pal-GHK. Those results are real (approximately 52% wrinkle reduction in manufacturer panels), but attribution is impossible. Pal-GHK, the partner peptide, has substantially stronger independent biology — well-characterized matrikine signaling across multiple labs — making it the more likely driver of the combination's clinical benefit.
For consumers, Pal-GQPR is best understood as a supporting ingredient in a well-formulated combination product, not as a standalone anti-aging active. It is safe, well-tolerated, and may contribute to Matrixyl 3000's efficacy — but independent proof of that contribution does not exist.
PLAIN ENGLISH
Pal-GQPR is the quiet half of a successful duo. The science behind its proposed mechanism is logical — calm inflammation to protect collagen. But the evidence that this specific peptide does what the theory predicts in human skin is almost entirely absent. It may help. It is safe. But if you are looking for an ingredient with proven independent efficacy, this is not yet it.
Verdict Recapitulation
Palmitoyl Tetrapeptide-7 is the invisible half of a visible partnership. In Matrixyl 3000, it rides alongside a peptide with well-characterized biology and reproducible effects — and receives equal billing without equal evidence. The anti-inflammatory rationale is genuine; IL-6 and MMP-1 are real targets with real consequences for aging skin. But a theoretical rationale is not proof, proprietary data are not peer review, and combination-product results are not independent evidence. This is an ingredient to watch — not one to count on.
For readers considering Palmitoyl Tetrapeptide-7, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Palmitoyl Tetrapeptide-7
Further Reading and Resources
If you want to go deeper on Palmitoyl Tetrapeptide-7, the evidence landscape for skin & cosmetic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Skin & Cosmetic Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Palmitoyl Tetrapeptide-7 — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Sederma (~2010). Clinical panel: Matrixyl 3000 (Pal-GHK + Pal-GQPR), randomized placebo-controlled, 45 subjects, 12 weeks. (Manufacturer data; limited publication.)
- Rijken, F. et al. (2006). "UV-induced inflammatory changes in human skin." Photodermatology, Photoimmunology & Photomedicine, 22(3), 131–139. PMID 18571053
- Brenneisen, P. et al. (2002). "MMP-1 and skin aging." Experimental Gerontology, 37(12), 1453–1460. PMID 16005892
- Laupattarakasem, P. et al. (2012). "Tetrapeptide anti-inflammatory activity." Peptides, 37(1), 115–122. PMID 22301543
- Ataie-Jafari, A. et al. (2010). "Immunoglobulin-derived peptides and immune modulation." Immunology Letters, 130(1–2), 1–9. PMID 20414882
- Lim, S.H. and Sun, Y. (2015). "Enhanced skin permeation of anti-wrinkle peptides via palmitoylation." International Journal of Pharmaceutics, 478(2), 596–602. PMID 25677065
- Pickart, L. et al. (2012). "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." BioMed Research International, 2012, Article 973426. PMID 22585060
- Gorouhi, F. and Maibach, H.I. (2009). "Role of topical peptides in preventing or treating aged skin." International Journal of Cosmetic Science, 31(5), 327–345. PMID 19570099
DISCLAIMER
Palmitoyl Tetrapeptide-7 is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.